An Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

About this Study

The study will compare three experimental drugs, crizotinib, cabozantinib and savolitinib to the standard treatment of sunitinib in the treatment of advanced kidney cancer.

Sponsor Protocol ID:S1500
IRB Number:2017-0130
Actively Enrolling
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
Both Male and Female
Yes
No
No

Inclusion Criteria

Women and minorities 

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials